Examples include monoamine oxidase inhibitors (MAOIs) and blood pressure drugs. Talk with your doctor ... Create a medication list, which your doctor and pharmacist can help you fill out.

Sumatriptan and others are contraindicated in patients taking monoamine oxidase (MAO) inhibitors or within 2 ... triptan or an ergotamine-containing drug is used because vasoconstriction could ...

There were more grade 3/4 drug-related adverse events, however, coming in at 18.9% in the combination arm compared to 9.7% with Opdivo, and discontinuation rates were 14.6% and 6.7%, respectively.

They describe the strength of evidence as compelling, highlighting the therapeutic potential of maintaining CDK4/6 inhibitor treatment when combating drug-resistant breast cancer. They also highlight ...

So the two key questions in protease-based drug discovery are: how specific should an inhibitor be to deliver a therapeutic outcome and what are the best ways to achieve the specificity needed?

Fintepla has interactions with alcohol, some other drugs, and certain supplements, including selective serotonin reuptake inhibitors (SSRIs ... called an MAOI. This is because taking Fintepla ...

This list is called a formulary. You can use it when comparing plans. Share on Pinterest alvarez/Getty Images Covered drugs are arranged by cost in tiers or levels. Generics are in the lowest ...

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

For this study, researchers focused on the SGLT-2 drug dapagliflozin ... “We hypothesized that SGLT-2 inhibitor plus moderate calorie restriction could achieve more body weight reduction ...

Dolutegravir is not an inducer or inhibitor of CYP450 or uridine diphosphate glucuronosyltransferase enzymes and therefore is associated with few drug interactions other than metformin and dofetilide.

The hope is that the two drugs could be combined with new KRAS inhibitor drugs from Amgen and Mirati to improve their efficacy, as well as potentially a dual therapy for other cancers. BridgeBio ...